×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Max Healthcare Institute Limit | 7738.7 | 1660.3 | 6940.2 | 1.7 | 1,11,767 | 93.2 |
| Mankind Pharma Limited | 26055.8 | 4127.6 | 25413.6 | 9.99 | 106467 | 56.3 |
| DR.REDDYS LABORATORIES LTD. | 88624.0 | 14099.0 | 85721.0 | 17.02 | 106162 | 18.7 |
Max Healthcare Institute Limited, with Security Code 543220, is a leading player in the Hospital industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 507.3 | 543.6 | 596.9 | 590.8 | 610.1 | 621.4 | 686.1 | 697.4 | 658.7 | 694.0 |
| Expenses | 353.5 | 384.0 | 394.0 | 390.6 | 410.7 | 423.3 | 461.4 | 461.4 | 484.1 | 506.3 |
| Operating Profit | 153.8 | 159.6 | 202.8 | 200.2 | 199.4 | 198.1 | 224.7 | 236.0 | 174.6 | 187.7 |
| OPM % | 30.32% | 29.36% | 33.98% | 33.88% | 32.69% | 31.88% | 32.75% | 33.85% | 26.51% | 27.05% |
| Other Income | 40.6 | 42.7 | 48.0 | 42.7 | 137.8 | 42.9 | 133.5 | 18.4 | 98.2 | 79.9 |
| Interest | 13.5 | 13.7 | 13.2 | 10.0 | 14.7 | 7.6 | 7.9 | 23.5 | 9.4 | 9.3 |
| Depreciation | 29.9 | 27.7 | 27.6 | 29.5 | 31.8 | 30.1 | 32.2 | 32.8 | 36.1 | 35.4 |
| Profit before tax | 151.0 | 161.0 | 210.0 | 203.3 | 290.6 | 203.2 | 318.2 | 271.8 | 227.3 | 222.9 |
| Tax % | -16.3% | -21.7% | -23.2% | -22.2% | -16.8% | 24.1% | -27.3% | -30.2% | -21.9% | 25.5% |
| Net Profit | 126.4 | 126.1 | 161.3 | 158.1 | 241.8 | 154.1 | 231.3 | 138.2 | 177.4 | 166.0 |
| EPS in Rs | 1.3 | 1.29 | 1.66 | 1.62 | 2.48 | 1.58 | 2.37 | 1.41 | 0 | 1.7 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,141.2 | 1,214.5 | 1,285.0 | 1,363.2 | 1,335.0 | 1,422.9 | 1,543.0 | 1,707.5 | 1,868.3 | 1,909.7 |
| Expenses | 827.8 | 874.2 | 947.6 | 975.8 | 949.1 | 1,041.4 | 1,155.5 | 1,256.9 | 1,369.2 | 1,398.1 |
| Operating Profit | 313.5 | 340.3 | 337.4 | 387.4 | 385.9 | 381.5 | 387.4 | 450.5 | 499.1 | 511.7 |
| OPM % | 27.47% | 28.02% | 26.26% | 28.42% | 28.9% | 26.81% | 25.11% | 26.39% | 26.72% | 26.79% |
| Other Income | 45.2 | 40.2 | 41.3 | 45.5 | 46.0 | 45.3 | 34.7 | 40.8 | -40.3 | 46.9 |
| Interest | 20.1 | 19.5 | 19.4 | 8.5 | 11.2 | 20.7 | 23.9 | 33.5 | 52.4 | 55.2 |
| Depreciation | 57.0 | 60.4 | 55.8 | 57.9 | 61.0 | 70.3 | 76.9 | 84.2 | 97.5 | 100.8 |
| Profit before tax | 281.4 | 300.7 | 303.5 | 366.4 | 359.7 | 335.7 | 321.3 | 373.7 | 382.5 | 402.6 |
| Tax % | -21% | -16.5% | -20.9% | -24.5% | -19.6% | -25.1% | -26.5% | 24.6% | 22.7% | -20.7% |
| Net Profit | 222.4 | 250.9 | 240.1 | 276.7 | 289.3 | 251.5 | 236.3 | 281.8 | 238.8 | 319.0 |
| EPS in Rs | 2.29 | 2.58 | 2.46 | 2.84 | 2.97 | 2.58 | 2.42 | 2.88 | 2.44 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 114% |
| 3 Years: | 14% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 203% |
| 3 Years: | 32% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 47% |
| 1 Year: | 43% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 30% |
| 3 Years: | 21% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 64% |
| 3 Years: | 23% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 47% |
| 1 Year: | 43% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|